Unknown

Dataset Information

0

Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer.


ABSTRACT: Background: Single-agent capecitabine (C) is a moderately effective chemotherapeutic compound in the treatment of patients with HER2-negative metastatic breast cancer (mBC). The capecitabine-vinorelbine (CV) combination is also used due to a good tolerability profile, but no studies have demonstrated its superiority over single-agent C. Methods: We conducted a retrospective analysis to compare overall response rate (ORR), progression-free survival (PFS), overall survival (OS) and incidence of adverse events (AEs) in patients with HER2-negative mBC treated with CV vs. single-agent C. Results: Out of 290 patients included in this study, 127 (43.8%) received single-agent C, while 163 (56.2%) patients were treated with CV. Median PFS was similar in patients treated with single-agent C or CV, while CV was associated with significantly longer OS in patients with hormone receptor-positive (HR+) BC. This OS advantage was confirmed at multivariable analysis also after propensity score-based matching of patients according to relevant clinical or tumor characteristics. When compared with single-agent C, CV was associated with higher incidence of G3/G4 and any-grade nausea/vomiting, diarrhea and increased transaminases. Conclusions: While prospective studies are needed to confirm our findings, the potential OS advantage of CV over single-agent C in HR+ mBC patients must be weighed against a significantly higher incidence of AEs.

SUBMITTER: Vernieri C 

PROVIDER: S-EPMC7139362 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications


<i>Background</i>: Single-agent capecitabine (C) is a moderately effective chemotherapeutic compound in the treatment of patients with HER2-negative metastatic breast cancer (mBC). The capecitabine-vinorelbine (CV) combination is also used due to a good tolerability profile, but no studies have demonstrated its superiority over single-agent C. <i>Methods</i>: We conducted a retrospective analysis to compare overall response rate (ORR), progression-free survival (PFS), overall survival (OS) and i  ...[more]

Similar Datasets

| S-EPMC10891320 | biostudies-literature
| S-EPMC6751874 | biostudies-literature
| S-EPMC8342589 | biostudies-literature
| S-EPMC5764151 | biostudies-literature
| S-EPMC8419118 | biostudies-literature
| S-EPMC11335038 | biostudies-literature
| S-EPMC3986598 | biostudies-literature
| S-EPMC5328303 | biostudies-literature
| S-EPMC5705195 | biostudies-literature